company background image
ITRM

Iterum Therapeutics NasdaqCM:ITRM Stock Report

Last Price

US$1.46

Market Cap

US$17.9m

7D

5.0%

1Y

-76.8%

Updated

07 Feb, 2023

Data

Company Financials +

Iterum Therapeutics plc

NasdaqCM:ITRM Stock Report

Mkt Cap: US$17.9m

ITRM Stock Overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.

ITRM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Iterum Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Iterum Therapeutics
Historical stock prices
Current Share PriceUS$1.46
52 Week HighUS$7.05
52 Week LowUS$0.60
Beta1.61
1 Month Change56.99%
3 Month Change2.46%
1 Year Change-76.83%
3 Year Change-96.20%
5 Year Changen/a
Change since IPO-99.24%

Recent News & Updates

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Aug 19
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Aug 12

Recent updates

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Aug 19
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Aug 12

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Jul 11

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

May 06
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Jan 12
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Sep 25
Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Jul 05

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Jun 11
It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

May 20
Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

Feb 04
Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Feb 04
This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Iterum Therapeutics shares slide 13% on raising $10M

Feb 03

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Dec 03

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Nov 30

Iterum Therapeutics EPS beats by $0.45

Nov 16

Shareholder Returns

ITRMUS PharmaceuticalsUS Market
7D5.0%-0.7%0.9%
1Y-76.8%4.9%-10.9%

Return vs Industry: ITRM underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.

Return vs Market: ITRM underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is ITRM's price volatile compared to industry and market?
ITRM volatility
ITRM Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: ITRM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ITRM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201513Corey Fishmanhttps://www.iterumtx.com

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics plc Fundamentals Summary

How do Iterum Therapeutics's earnings and revenue compare to its market cap?
ITRM fundamental statistics
Market CapUS$17.86m
Earnings (TTM)-US$43.53m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ITRM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$43.53m
Earnings-US$43.53m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.56
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio92.8%

How did ITRM perform over the long term?

See historical performance and comparison